Company Overview
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $20.96M (-5.7% YoY); net profit $-44.63M.
- Trailing 12 Months Year-on-year growth — revenue -7.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.93% |
| 1 Year: | -7.10% |
Stock Price Performance
| 1 Year: | -7.25% |
| 6 Months: | +63.68% |
| 3 Months: | +12.28% |
| 1 Month: | +15.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 30.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MXCT MaxCyte, Inc. R2KPHARMA | 1.28 | -3.56 | $137.12M | 0.00% | -27.57% | -21.30% | 7.93% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.33M | 4.67M | 4.24M | 4.22M | 5.61M | 6.86M | 6.98M | 7.15M | 4.96M | 5.62M | 4.16M | 5.58M | 4.96M | 5.61M | 5.74M | 5.82M | 4.60M | 4.50M |
| Gross Profit | - | 4.68M | 6.03M | 5.80M | 6.32M | 9.20M | 10.52M | 8.49M | 9.27M | 7.58M | 7.67M | 7.21M | 9.94M | 8.94M | 6.24M | 8.89M | 6.99M | 5.23M | 8.08M |
| Operating Income | - | -2.84M | -2.84M | -6.37M | -4.42M | -2.44M | -4.16M | -8.74M | -7.71M | -13.18M | -13.07M | -13.95M | -12.28M | -11.97M | -14.05M | -12.29M | -14.23M | -14.15M | -6.18M |
| Net Income | -3.06M | -3.00M | -3.10M | -7.11M | -4.42M | -2.68M | -4.07M | -8.26M | -6.43M | -10.88M | -10.51M | -11.25M | -9.53M | -9.38M | -11.56M | -10.26M | -12.36M | -12.42M | -4.75M |
| Diluted EPS | - | -0.05 | -0.04 | -0.09 | -0.05 | -0.03 | -0.04 | -0.08 | -0.06 | -0.11 | -0.10 | -0.11 | - | -0.09 | -0.11 | -0.10 | -0.12 | -0.12 | -0.04 |
| R&D Expense | - | 4.09M | 4.52M | 6.08M | 3.20M | 2.75M | 3.77M | 4.70M | 5.33M | 6.05M | 5.66M | 6.26M | 6.68M | 5.62M | 5.32M | 5.90M | 6.27M | 5.32M | 3.86M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 13.26M | 15.45M | 21.57M | 28.75M | 19.50M | 22.21M | 20.96M |
| Gross Profit | 19.12M | 23.40M | 30.25M | 39.16M | 36.55M | 31.53M | 26.80M |
| Operating Income | -12.42M | -11.06M | -18.19M | -27.36M | -48.30M | -51.20M | -51.90M |
| Net Income | -12.89M | -11.82M | -19.08M | -23.57M | -37.92M | -41.05M | -44.63M |
| Diluted EPS | -0.23 | -0.17 | -0.21 | -0.23 | -0.37 | -0.39 | -0.42 |
| R&D Expense | 17.59M | 17.73M | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 51.78M | 284.12M | 286.65M | 268.27M | 239.47M | 202.51M |
| Total Equity | 12.28M | 13.60M | 33.23M | 262.90M | 253.97M | 232.17M | 206.25M | 171.49M |
| Cash & Equivalents | - | - | 18.76M | 47.78M | 11.06M | 46.51M | 27.88M | 20.07M |
| Total Liabilities | - | - | 18.55M | 21.22M | 32.69M | 36.11M | 33.22M | 31.02M |
| Current Liabilities | - | - | 11.61M | 15.62M | 15.43M | 17.86M | 15.78M | 14.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.80M | -8.78M | -10.68M | -14.78M | -21.69M | -27.61M | -34.41M |
| Investing Cash Flow | 454.50K | -16.58M | -195.01M | -24.82M | 54.98M | 6.93M | 25.93M |
| Financing Cash Flow | 12.31M | 28.90M | 234.72M | 2.89M | 2.14M | 2.06M | 656.00K |
| Capital Expenditure | -1.27M | -2.07M | -3.83M | -18.48M | -3.70M | -1.65M | -1.77M |
| Free Cash Flow | -10.07M | -10.85M | -14.51M | -33.26M | -25.39M | -29.26M | -36.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 144.2% | 151.5% | 140.2% | 136.2% | 187.4% | 141.9% | 127.9% |
| Operating Margin % | -93.7% | -71.6% | -84.3% | -95.2% | -247.7% | -230.5% | -247.6% |
| Net Margin % | -97.3% | -76.5% | -88.5% | -82.0% | -194.5% | -184.8% | -213.0% |
| ROE % | -94.8% | -35.6% | -7.3% | -9.3% | -16.3% | -19.9% | -26.0% |
| ROCE % | - | -27.5% | -6.8% | -10.1% | -19.3% | -22.9% | -27.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Capricorn Fund Managers Ltd | 7.95% | 8.20M | $10.00M |
| 2 | Vitruvian Partners, LLP | 4.89% | 5.04M | $6.15M |
| 3 | Vanguard Capital Management LLC | 3.91% | 4.03M | $4.92M |
| 4 | Morgan Stanley | 3.58% | 3.69M | $4.51M |
| 5 | Mudita Advisors LLP | 3.27% | 3.37M | $4.11M |
| 6 | Blackrock Inc. | 2.97% | 3.06M | $3.73M |
| 7 | Brooklands Fund Management Ltd | 2.76% | 2.85M | $3.47M |
| 8 | BNP Paribas Asset Management Holding S.A. | 2.69% | 2.77M | $3.38M |
| 9 | Cadian Capital Management, LP | 2.13% | 2.20M | $2.69M |
| 10 | Peapod Lane Capital LLC | 2.06% | 2.13M | $2.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MXCT
MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNSEpOclkxYXFuczVVMW94TFBOSFpjX0toTXVUd1dETHZNNHR5Q2lCVnZfTVI0bkhpMW9lblV2R2hxNVJMNTFYT3owUXVoOUJ2U3RobDlkTjBJV0NKcUFHSkwtU01YRjZKOW5RemI5UUFYTVM0bVMtb0t1Yzc2dng4OGJQN3Nqd2pwQmMtVG…
$MXCT stock is up 19% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPdDE5VHdXWnpuLV9LdmM2d3oxLXJscEtJeUppTFl1My03LW4yTG9rMVFNV2Ztd0syOVNBTHo2OXJHVDJjTFgtOGF5aU1QOXliNndlbjJGNFdzVFJSZ2w2OXVCNjZPWElHcGoybXBmR1RUcG1GdlJrY3NQRXJXTEg2MHh5UjhBYzhyM2J5bW…
MXCT stock holds steady as MaxCyte focuses on cell-therapy growth - ad-hoc-news.de
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNVlVmX256cjBfSC1mbVp1M1JSMjdtWXlNc0ZnM09RR3lLQjBMbkx3c2VGYVU3TkJMMWN2R1gzOWpDUTFGa0FZdHJXeUxXVDlZYWxxdlpmWC1veEpfNmk2eEJlQk1LQUdCdlZQLXRkNTdmbGwwaW9pbVkxc09DakpwQkJ0dW1nbGF6QzFTZV…
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaEEyWDRlVU5vVlM3alBRZkVIY0NuWngtMXN5eTBxSFlEYkFWMEVqZU5BbFdTTk1vb2FYQmZPVG1oblBRZzlnX2FsUVdKVEcwWkd2RlM1V2xGOWhYX1Z2T1lNSXpKYTdESUd4cmFpN0tHWXFwOGptdnJ0Tm4zMnBLcmJuSnFUQ0VOdTZybT…
MXCT Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5Cel8welpRS3hBbHVzUEQ3X2FYeWtlMnp6aVVQUjhqUVpaZ1RudmZ6UWhUa2hBWDdiNjZtV2NLZUhjYzd1T0JMajRVVGVWZXFhSXotUkVVUE4yU3JhSnlrbkhyOTdWcldmX3hVbTJvdWNpd1l1ME9UVGVR?oc=5" target="_blank">MXC…
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQRHlodzdWbHk5N0JsT25sVHhyWVZtUllEZThZLXJUUUQteWlvcTFaLUZja0QyUU12Y3VGLTYyNjF3Z3RkRGFta0NkTzlmWkNYSm5ISXVpa1BxYW9JVzdRcDNtVTZiUWtZNk9TeDlBX2xzQmJMV0hTaHhxSUtSYnJwYW5HWk5ZaXdkRkY2dE…
MXCT — Frequently Asked Questions
What is the current share price of MaxCyte, Inc. (MXCT)?
As of 2026-09-07 16:24 PDT, MaxCyte, Inc. (MXCT) trades at $1.28 on NasdaqGS. Its 52-week range is $0.68 to $1.83.
What is the market capitalisation of MXCT?
MaxCyte, Inc. (MXCT) has a market capitalisation of $137.12M on NasdaqGS.
What is the P/E ratio of MXCT?
MXCT trades at a trailing price-to-earnings (P/E) ratio of -3.56. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.75.
What is the return on equity (ROE) of MXCT?
MXCT has a return on equity (ROE) of -21.30%. Its return on capital employed (ROCE) is -27.57%.
Is MXCT a good stock to buy?
This page provides a data-driven analysis of MaxCyte, Inc. (MXCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.